OBJECTIVES: To evaluate utilization of surgery, chemotherapy, and radiation therapy among patients with stage II or III colon cancer and stage II/III rectal or rectosigmoid cancer, as recommended by current national guidelines. METHODS: This cross-sectional study at the Michael E. DeBakey Veterans Affairs Medical Center (Houston, TX) used 1999-2003 administrative data to identify patients with a diagnostic code for colorectal cancer. Medical charts were then abstracted to identify an incident cohort with stage II or III cancer. Outcome of interest was receipt of recommended therapy defined as surgery only (stage II colon) or surgery with adjuvant chemo- or radiotherapy (stage III colon or stage II/III rectal/rectosigmoid cancer). Potential determinants of receipt of recommended therapy were analyzed using logistic regression. RESULTS: Among 197 incident cases diagnosed or treated, mean age of patients was 66 yr (SD, 11 yr), 64% were Caucasian, and 98.5% were men. A gastroenterologist diagnosed 72.5% tumors including 62 stage II colon, 62 stage III colon, and 73 stage II/III rectal cancers. Referral to oncology occurred in 76% of stage II colon, 92% of stage III colon, and 99% of rectal cancers. 87% of stage II and 71% of stage III colon cancer patients received recommended therapy, compared to only 42.5% of rectal cancer patients. Predictors of receipt of recommended therapy among rectal cancers included being married (OR, 5.3; 95% CI: 1.6-17.1), presentation at tumor board (OR, 3.6; 95% CI: 1.2-11.2), or age<65 yr (OR, 3.5; 95% CI: 1.3-9.3). When patient's comorbidity and physician's decision-making process were considered in the assessment of the outcome, only presentation at tumor board remained predictive of receipt of recommended therapy. CONCLUSIONS: Most colon cancer patients at a major VA medical center receive recommended therapy. Among rectal cancer patients, those presented at tumor board are most likely to receive recommended therapy.
OBJECTIVES: To evaluate utilization of surgery, chemotherapy, and radiation therapy among patients with stage II or III colon cancer and stage II/III rectal or rectosigmoid cancer, as recommended by current national guidelines. METHODS: This cross-sectional study at the Michael E. DeBakey Veterans Affairs Medical Center (Houston, TX) used 1999-2003 administrative data to identify patients with a diagnostic code for colorectal cancer. Medical charts were then abstracted to identify an incident cohort with stage II or III cancer. Outcome of interest was receipt of recommended therapy defined as surgery only (stage II colon) or surgery with adjuvant chemo- or radiotherapy (stage III colon or stage II/III rectal/rectosigmoid cancer). Potential determinants of receipt of recommended therapy were analyzed using logistic regression. RESULTS: Among 197 incident cases diagnosed or treated, mean age of patients was 66 yr (SD, 11 yr), 64% were Caucasian, and 98.5% were men. A gastroenterologist diagnosed 72.5% tumors including 62 stage II colon, 62 stage III colon, and 73 stage II/III rectal cancers. Referral to oncology occurred in 76% of stage II colon, 92% of stage III colon, and 99% of rectal cancers. 87% of stage II and 71% of stage III colon cancerpatients received recommended therapy, compared to only 42.5% of rectal cancerpatients. Predictors of receipt of recommended therapy among rectal cancers included being married (OR, 5.3; 95% CI: 1.6-17.1), presentation at tumor board (OR, 3.6; 95% CI: 1.2-11.2), or age<65 yr (OR, 3.5; 95% CI: 1.3-9.3). When patient's comorbidity and physician's decision-making process were considered in the assessment of the outcome, only presentation at tumor board remained predictive of receipt of recommended therapy. CONCLUSIONS: Most colon cancerpatients at a major VA medical center receive recommended therapy. Among rectal cancerpatients, those presented at tumor board are most likely to receive recommended therapy.
Authors: Denise M Hynes; Elizabeth Tarlov; Ramon Durazo-Arvizu; Ruth Perrin; Qiuying Zhang; Thomas Weichle; M Rosario Ferreira; Todd Lee; Al B Benson; Nirmala Bhoopalam; Charles L Bennett Journal: J Clin Oncol Date: 2010-04-20 Impact factor: 44.544
Authors: Xanthoula Kostaras; Melissa A Shea-Budgell; Emily Malcolm; Jacob C Easaw; Wilson Roa; Neil A Hagen Journal: J Cancer Educ Date: 2012-03 Impact factor: 2.037
Authors: Nicole J Look Hong; Anna R Gagliardi; Susan E Bronskill; Lawrence F Paszat; Frances C Wright Journal: J Oncol Pract Date: 2010-03 Impact factor: 3.840
Authors: Kenneth L Kehl; Mary Beth Landrum; Katherine L Kahn; Stacy W Gray; Aileen B Chen; Nancy L Keating Journal: J Oncol Pract Date: 2015-04-28 Impact factor: 3.840
Authors: Cynthia Gail Leichman; Shannon L McDonough; Stephen R Smalley; Kevin G Billingsley; Heinz-Josef Lenz; Matthew A Beldner; Aram F Hezel; Mario R Velasco; Katherine A Guthrie; Charles D Blanke; Howard S Hochster Journal: Clin Colorectal Cancer Date: 2017-10-24 Impact factor: 4.481
Authors: Nancy L Keating; Mary Beth Landrum; Elizabeth B Lamont; Samuel R Bozeman; Lawrence N Shulman; Barbara J McNeil Journal: J Natl Cancer Inst Date: 2012-12-28 Impact factor: 13.506
Authors: Carol M Lewis; Amy C Hessel; Dianna B Roberts; Yunxia Z Guo; F Christopher Holsinger; Lawrence E Ginsberg; Adel K El-Naggar; Randal S Weber Journal: Arch Otolaryngol Head Neck Surg Date: 2010-12
Authors: Debrah A Wirtzfeld; Lynn Mikula; Robert Gryfe; Pietro Ravani; Elizabeth L Dicks; Pat Parfrey; Steve Gallinger; William G Pollett Journal: Can J Surg Date: 2009-04 Impact factor: 2.089